



Patent Application
Attorney Docket No. PC27510A

I hereby certify that this correspondence is being deposited as first-class mail with the United States Postal Service, and is addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of June 2004.

By

(Signature of person transmitting)

A. David Joran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jon Gordon Selbo :

APPLICATION NO.: 10/729,286 : Examiner:

FILING DATE: December 5, 2003 : Group Art Unit:

TITLE: CRYSTALLINE FUMARATE SALTS OF :
1-AZABICYCLO[2.2.2]OCT
SUBSTITUTED FURO[2,3-
C]PYRIDINYL CARBOXAMIDE AND
COMPOSITIONS AND PREPARATIONS
THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.


INFORMATION DISCLOSURE STATEMENT, 05/03, (1/2)

A prompt and favorable response is earnestly solicited.

Date:

June 1, 2004

Respectfully submitted,



A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733 -3381



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC27510A	SERIAL NO. 10/729,286
	APPLICANT Jon Gordon Selbo	
	FILING DATE December 5, 2003	GROUP

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
													YES NO
	WO	0	4	7	3	4	3	1	5/25/00	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
			Sandra T. Cooper, et al., "Host Cell-Specific Folding and Assembly of the Neuronal Nicotinic Acetylcholine Receptor $\alpha 7$ Subunit", J. Neurochem. 68, pp 2140-51 (1997)										
			Jean-Luc Elele, et al., "Chimaeric Nicotinic Serotonergic Receptor Combines Distinct Ligand Binding and Channel Specificities", Nature, 366, pp. 479-83 (1993)										
			Timothy E. Wilens, et al., "A Pilot Controlled Clinical Trial of ABT-418, a Cholinergic Agonist, in the Treatment of Adults with Attention Deficit Hyperactivity Disorder", Am. J. Psychiatry, 156, pp 1931-37 (1999)										
			Lawrence E. Adler, et al., "Normalization of Auditory Physiology by Cigarette Smoking in Schizophrenic Patients", Am. J. Psychiatry, 150, pp 1856-61 (1993)										
			Edward D. Levin, "Nicotinic Systems and Cognitive Function", Psychopharmacology, 108, pp 417-31 (1992)										

EXAMINER	DATE CONSIDERED
+	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.